• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Daratumumab regimen improves survival in transplant-ineligible multiple myeloma

by | Mar 27, 2025 | Uncategorized

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed.The findings, published in Nature Medicine, support quadruplet therapy with subcutaneous daratumumab...

Communication is Key When Transitioning Multiple Myeloma Care

by | Mar 26, 2025 | Uncategorized

Source: CureToday articles A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit. Read More

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

by | Mar 18, 2025 | Uncategorized

Source: CureToday articles Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma. Read More

First relapse in multiple myeloma: the patient perspective

by | Mar 18, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease

by | Mar 14, 2025 | Uncategorized

Source: CureToday articles Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month. Read More

Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma

by | Mar 10, 2025 | Uncategorized

Source: CureToday articles Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE. Read More
« Older Entries
Next Entries »

Recent Content

  • “Chillin’ Out” and Finding Our Cancer Community
  • AAN 2025: Pharmacists Play Critical Role in Monitoring, Managing Lecanemab Therapy
  • Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
  • Risk of lymphoid malignancy associated with cancer predisposition genes
  • Large-scale human myeloma cell line small molecule compound screen dataset
  • Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
  • PCV10 Elicits Durable Immune Response in T2D, Though Response Remains Inferior to Non-Diabetics
  • AAN 2025: Insights on Pediatric Multiple Sclerosis Treatment and Management
  • Illuminating Compassion in Cancer Care
  • Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT